Evidence map›Paper›PMID 16148179›Full record

ArticleClinical and diagnostic laboratory immunology2005

Monoclonal antibodies against Enterocytozoon bieneusi of human origin.

Abhineet S Sheoran, Xiaochuan Feng, Inderpal Singh, Susan Chapman-Bonofiglio, Sabrina Kitaka, Joel Hanawalt, John Nunnari, Keith Mansfield, James K Tumwine, Saul Tzipori

Open access · diamondAbstract read
In one paragraph

Article in Clinical and diagnostic laboratory immunology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Identification and Characterization of Three Spore Wall Proteins ofFrontiers in cellular and infection microbiology · 2022
    Article
  2. Ecological and public health significance ofOne health (Amsterdam, Netherlands) · 2021
    Review
  3. Article
  4. Article
  5. Article
  6. Molecular diagnostic tests for microsporidia.Interdisciplinary perspectives on infectious diseases · 2009
    Article
  7. Microsporidiosis: current status.Current opinion in infectious diseases · 2006
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Abhineet S SheoranDivision of Infectious Diseases, Tufts University School of Veterinary Medicine, North Grafton, MA 01536, USA.
Xiaochuan Feng
Inderpal Singh
Susan Chapman-Bonofiglio
Sabrina Kitaka
Joel Hanawalt
John Nunnari
Keith Mansfield
James K Tumwine
Saul Tzipori
Makerere University · UGMulago Hospital · UGTufts University · US

Funding

Wasting, nutritional status, and micronutrientsP01DK055510 · NIDDK · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI MANSFIELD, KEITH G. · 2000 to 2004
$5.8M
PIG MODEL FOR E BIENEUSIR01AI043196 · NIAID · TUFTS UNIVERSITY BOSTON · PI TZIPORI, SAUL R · 1998 to 2002
$971k
Generation of Reagents for E. bieneusi Genome SequencingR21AI052792 · NIAID · TUFTS UNIVERSITY BOSTON · PI TZIPORI, SAUL R · 2002 to 2003
$464k
NIAID NIH HHS R01AI43196NIAID NIH HHS R21 AI052792NIAID NIH HHS R21AI52792NIDDK NIH HHS P01 DK055510NIDDK NIH HHS P01DK55510
6 · The paper itself

Abstract

Enterocytozoon bieneusi is clinically the most significant among the microsporidia infecting humans, causing chronic diarrhea, wasting, and cholangitis in individuals with human immunodeficiency virus/AIDS. The lack of immune reagents is largely due to the absence of methods for laboratory propagation of E. bieneusi. We recently described a procedure for the concentration and purification of spores from diarrheic stool of infected humans. Purified spores were used to immunize mice for production and screening of monoclonal antibodies (MAbs) against E. bieneusi. The eight immunoglobulin M MAbs generated and fully characterized did not cross-react with other human microsporidia or with other microorganisms normally present in stool. One of the MAbs, 2G4, reacted with E. bieneusi spores in stools from monkeys and humans, without background fluorescence, which makes it an ideal diagnostic reagent. It also recognizes intracellular stages of the parasite and will be suitable for determining tissue distribution of E. bieneusi in infected hosts. At least two immunodominant antigens of E. bieneusi of 33,000 and 35,000 Da exist, which were recognized by rabbit and mouse antisera. The availability of MAbs against E. bieneusi will simplify considerably the diagnosis of this infection in humans and will provide tools for epidemiologic investigations regarding the true prevalence of the infection in various human and mammalian populations and the environmental sources of infection.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, ProtozoanAntibody SpecificityAntigens, ProtozoanCross ReactionsDiarrheaEnterocytozoonFecesFemaleHumansImmunoglobulin MMiceMice, Inbred BALB CMicrosporidiosisSpores, ProtozoanAntibodies, MonoclonalAntibodies, ProtozoanAntigens, ProtozoanImmunoglobulin M

Identifiers

PMID16148179
PMCPMC1235791
OpenAlexW2147397980

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.